LegiStorm

Summary:

Colombia is one of the largest producers of cocaine globally, and it also produces heroin bound for the United States. Counternarcotics policy has long been a key component of the U.S.- Colombian relationship, which some analysts have described as “driven by drugs.” In recent years, Colombia revised its approach to counternarcotics policy, which may have implications for the U.S.-Colombian relationship going forward. On September 13, 2017, President Trump cited the recent spike in Colombia’s cocaine production as the reason he was reserving the option to decertify Colombia as a cooperating partner in fighting illegal drugs, an unexpected development given the close counternarcotics partnership between the United States and Colombia. U.S. concerns about illicit drug production and trafficking in Colombia arose in the 1970s and grew significantly when Colombia became the dominant producer of cocaine in the Andean region in the mid-to-late 1990s. The United States has worked closely with Colombia to eradicate drug crops and combat trafficking. Simultaneously, since 2000, the United States has forged a partnership with Colombia—perhaps its closest bilateral relationship in Latin America—centered on helping Colombia recover its stability following a decades-long internal conflict with insurgencies of left-wing guerrillas and right-wing paramilitaries, whose longevity has been attributed, in part, to their role in the country’s illicit drug trade. Between FY2000 and FY2016, the U.S. Congress appropriated more than $10 billion of bilateral foreign assistance to support a Colombian-written strategy known as Plan Colombia and its successor programs. In addition to counternarcotics, the United States helped support security and development programs designed to stabilize Colombia’s security situation and strengthen its democracy. A peace accord between the government of Colombia and the country’s main leftist insurgent group, the Revolutionary Armed Forces of Colombia (FARC), was signed in November 2016 after four years of formal peace talks. During protracted peace negotiations with the FARC, the Colombian government altered its approach to drug policy. A major change was the decision to end aerial spraying to eradicate coca crops, which had been a central—albeit controversial— feature of U.S.-Colombian counterdrug cooperation for more than two decades. In addition, Colombia’s counternarcotics policies also shifted in 2015 to a public health approach. The shift was influenced by broader hemispheric trends to reform traditional antidrug practices in ways that proponents claim can reduce human rights violations. On the supply side, Colombia’s new drug policy gives significant attention to expanding alternative development and licit crop substitution while intensifying interdiction efforts. The revised drug policy approach promotes drug-use prevention and treatment for drug users. According to Colombian officials, the public health and prevention dimensions of the revised strategy will be led by Colombia’s Health Ministry, in coordination with other agencies. In November 2016, Colombia’s Congress unanimously ratified the FARC-government peace accord, although some opponents boycotted that vote. The final accord was a revision following the narrow defeat of an earlier version of the accord in an October 2, 2016 referendum. The final peace agreement addresses important issues, such as illicit crop cultivation—a major source of FARC income—and rural development. According to President Juan Manuel Santos, the peace accord will draw former FARC members into efforts to counter illicit drug production and trafficking. In 2017, as Colombia began to implement the final peace accord and demobilize the FARC, the country is facing a large increase in cocaine production. This report examines how Colombia’s drug policies have evolved in light of Colombia’s peace agreement with the FARC and its changing counternarcotics policy. It explores both policy and oversight concerns, such as prospects for reducing coca and poppy cultivation under Colombia’s new drug policy and the peace accord with the FARC;  the role of Colombian drug trafficking organizations, including powerful criminal groups containing former paramilitaries, in a post-peace accord environment;  U.S.-Colombian cooperation on counternarcotics and Colombia’s future role in regional antidrug efforts; and  shifts in U.S. government assistance to support Colombia’s revised drug policy and how Colombia’s new policy converges with traditional U.S. priorities. For additional background, see CRS Report RL34543, International Drug Control Policy: Background and U.S. Responses, by Liana W. Rosen; CRS Report R43813, Colombia: Background and U.S. Relations, by June S. Beittel.